Long-term intraperitoneal deferoxamine for hemochromatosis

American Journal of Medicine

Volumn 100, Issue 3, 1996, Pages 308-312

  Swartz, Richard D ^a,b   Legault, Daniel J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FLECAINIDE; HLA ANTIGEN; MAGNESIUM; PENTOXIFYLLINE; PYRUVATE KINASE;

ADULT; ANTIGEN DETECTION; ARTICLE; ASCITES; BLOOD TRANSFUSION; CARDIOMYOPATHY; CASE REPORT; CHELATION THERAPY; CLINICAL FEATURE; ENZYME DEFICIENCY; FEMALE; HEMOCHROMATOSIS; HEMOLYTIC ANEMIA; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; IRON OVERLOAD; LABORATORY TEST; LIVER CIRRHOSIS; MEDICAL RECORD; NEEDLE BIOPSY; PERITONEAL DIALYSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCINTIANGIOGRAPHY;

EID: 0029940657     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89489-2     Document Type: Article

References (27)

1. Modell CB, Beck J. Long-term desferrioxamine therapy in thalassemia. Ann NY Acad Sci. 1974;232:201-210.
2. Propper RD, Cooper B, Rufo RR, et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. NEJM. 1977; 297:418-423.
3. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 1964;119:758-768.
4. Catsch A, Harmuth-Hoene A. Pharmacology and therapeutic application of agents used in heavy metal poisoning. In: Chelation of Heavy Metals. New York: Pergamon Press; 1979:133-137.
5. Andreoli S, Dunn D, DeMyer W. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing CAPD. J Pediat. 1985;107:760-763.
6. Hercz G, Salusky IB, Norris KC, et al. Aluminum removal by peritoneal dialysis: intravenous vs intraperitoneal deferoxamine. Kid Int. 1986;30: 944-948.
7. Taber TE, Hegeman TF, Miller R, York S. Treatment of iron overload in CAPD. Trans Am Soc Artif Organs. 1987;33:654-656.
8. Andreoli S, Cohen M. Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD. Kid Int. 1989;35:1330-1335.
9. Marcus RG, Messana JM, Swartz RD. Peritoneal dialysis in end-stage renal disease with pre-existing chronic liver disease and ascites. Am J Med. 1992; 93:35-40.
10. Rubin J, Ball R. CAPD as a treatment of severe congestive heart failure in the face of chronic renal failure. Arch Int Med. 1986;146:533-535.
11. Konig P, Geissler D, Lechleitner P, et al. Improved management of congestive heart failure: use of CAPD. Arch Int Med. 1987;147:1031-1034.
12. Korzets A, Danby P, Feehaily J, Watts J. CAPD: successful use in the treatment of nephrogenic ascites. Nephrol Dial Transpl. 1989;4:918-919.
13. Cintin C, Joffe P. Nephrogenic ascites: case report and review of the literature. Scand J Urol Nephrol. 1994;28:311-314.
14. Hammond TC, Takiyyuddin MA. Nephrogenic ascites: a poorly understood syndrome. J Am Soc Nephrol. 1994;5:1173-1177.
15. Easley RM, Schreiner BF, Yu PN. Reversible cardiomyopathy associated with hemochromatosis. NEJM. 1972;287:866-867.
16. Propper R, Sheirin S, Nathan D. Desferrioxamine B and iron overload. In: Anderson W, Hiller M, eds. Symposium on Development of Iron Chelators for Clinical Use. Publication no. 76-994. Washington DC: Dept. of Health, Education, and Welfare; 1975:83-114.
17. Hussain MAM, Flynn DM, Green N, Hoffbrand AV. Effect of dose, time and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet. 1977;1:977-979.
18. Falk RJ, Mattern WD, Lamanna RW, et al. Iron removal during CARD using deferoxamine. Kid Int. 1983;24:110-112.
19. Howell SB, Pfeifle CE, Olshen RA. Intraperitoneal chemotherapy with melphalan. Ann Int Med. 1984;101:14-18.
20. Schade DS, Eaton RP, Davis T, et al. The kinetics of peritoneal insulin absorption. Metabolism. 1980;30:149-155.
21. Ley TJ, Griffith P, Nienhuis AW. Transfusion haemosiderosis and chelation therapy. Clin Hematol. 1982;11:437-464.
22. Salem HH, Van Der Weyden MB, Firkin BG. Iron overload in congenital erythrocyte pyruvate kinase deficiency. Med J Austr. 1980;1:531-532.
23. Weintraub LR, Conrad ME, Crosby WH. Regulation of the intestinal absorption of iron by the rate of erythropoiesis. Brit J Haematol. 1965;2: 432-434.
24. de Alarcon PA, Donovan ME, Forbes GB, et al. Iron absorption in the thalassemia syndromes after its inhibition by tea. NEJM. 1979;300:5-8.
25. McCarthy JT, Kurtz SB, Mussman GV. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing CAPD. Am J Med. 1987;82:367-370.
26. Milman N, Graudal N, Nielsen L, Fenger K. An HLA study in 74 Danish haemochromatosis patients and in 21 of their families. Clin Genet. 1992;41:6-11.
27. Olivieri NF, Brittenham GM, Matsui D, et al. Iron chelation therapy with oral deferiprone in patients with thalassemia major. NEJM. 1995;332:918-922.